ANI Pharmaceuticals reported a remarkable performance in 2025, achieving total net revenues of $854 million to $873 million and adjusted non-GAAP EBITDA of $221 million to $228 million.
The Rare Disease segment exhibited exceptional growth, driven by Purified Cortrophin® Gel with net revenues of $347.8 million, representing a 76% year-over-year increase.
Looking ahead, ANI Pharmaceuticals sets ambitious financial targets for 2026, forecasting total net revenues in the range of $1,055 million to $1,115 million and Cortrophin Gel net revenues of $540 million to $575 million.
ANI's Resilient Growth in 2025
ANI delivered robust performance in 2025, achieving a minimum of 39% growth in total net revenues and 42% growth in adjusted non-GAAP EBITDA, underlining its operational strength and market position.
Strategic Focus on Rare Disease Expansion
ANI's strategic vision includes expanding its Rare Disease segment by augmenting its workforce by approximately 90 employees, aiming to capitalize on opportunities in acute gouty arthritis flares by mid-2026.
Bold Financial Targets for 2026
ANI anticipates surpassing the $1 billion mark in total net revenues for 2026, with the Rare Disease business expected to account for around 60% of the company's revenue stream, indicating a significant shift in revenue composition.
- ANI Pharmaceuticals is strategically solidifying its position as a dominant player in the Rare Disease sector, emphasizing its commitment to Cortrophin Gel, a key revenue driver for the company.
- The company's impressive growth trajectory in 2025 and ambitious financial projections for 2026 signal promising prospects for sustained financial performance and expansion in the competitive pharmaceutical landscape.
Driven by its strong 2025 performance and ambitious 2026 targets, ANI Pharmaceuticals is set to strengthen its market leadership in the Rare Disease segment. By focusing on strategic expansion and revenue diversification, the company aims to capitalize on evolving market demands and solidify its position as a key player in the pharmaceutical industry.